## TMO: Thermo Fisher Scientific Inc - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 -1.8% below STRENGTH zone (3.0-6.0%); PEG 1.95 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge. Caution: momentum weakening (-2.4% MRS).

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($557.95)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 3, Bearish: 0)

**1. Thermo Fisher Scientific Stock: Is TMO Outperforming the Health Care Sector?**
- Source: MSN | 20251130T183645 | Neutral | Relevance: 99%
- This article examines whether Thermo Fisher Scientific (TMO) is outperforming its sector peers. It compares TMO's year-to-date return of +5.92% to the S&P 500's +7.21% and the Medical sector's +5.31%, suggesting TMO is outperforming its sector but lagging the broader market. Key financial metrics like earnings growth, cash flow, and debt-to-equity are highlighted to provide a fundamental perspective on the company.

**2. Thermo Fisher Scientific issues €2.1 billion in euro-denominated senior notes By Investing.com**
- Source: Investing.com South Africa | 20251201T232800 | Bullish | Relevance: 98%
- Thermo Fisher Scientific's finance subsidiary has issued €2.1 billion in senior notes, comprising floating-rate notes due 2027 and fixed-rate notes due 2035. The proceeds are intended for general corporate purposes, including acquisitions, debt repayment, and share repurchases. This comes as Moody’s upgraded Thermo Fisher Scientific’s senior unsecured notes to A2 from A3, reflecting the company's strong financial health and strategic initiatives.

**3. Thermo Fisher Scientific (TMO) Stock on 1 December 2025: HSBC Upgrade, Insider Moves, Buyback and 2026–2030 Forecasts**
- Source: ts2.tech | 20251201T190803 | Somewhat-Bullish | Relevance: 98%
- This article analyzes Thermo Fisher Scientific (TMO) stock as of December 1, 2025, detailing an HSBC upgrade to "Buy," recent insider transactions, institutional investor moves, and a $5 billion share repurchase authorization. It also covers the company's Q3 2025 earnings beat, the strategic acquisition of Clario, and various analyst and algorithmic forecasts for its future performance through 2030. The piece concludes with a balanced view of the bullish and cautionary factors for TMO stock.

**4. 10 Best Dividend Stocks Hedge Funds Are Buying**
- Source: Insider Monkey | 20251130T120500 | Bullish | Relevance: 98%
- This article identifies Thermo Fisher Scientific Inc. (NYSE: TMO) as one of the best dividend stocks favored by hedge funds. It details the company's recent Euro-denominated note offering worth €2.1 billion to fund corporate expenditures and debt repayment, and highlights a "Buy" rating from Stifel Nicolaus with a $583 price target. Thermo Fisher Scientific is a Massachusetts-based company specializing in life sciences products, lab equipment, and biopharma services.

**5. HSBC Upgrades Thermo Fisher Scientific to Buy From Hold, Adjusts Price Target to $670 From $550**
- Source: MarketScreener | 20251201T052100 | Bullish | Relevance: 97%
- HSBC has upgraded Thermo Fisher Scientific's rating from Hold to Buy and increased its price target to $670 from $550. This positive analyst action reflects a more optimistic outlook for the company's stock performance. The article also provides recent news on insider transactions, note offerings, FDA approvals for diagnostic tests, and a significant share repurchase program.

### Analyst Activity

**Target Signal:** BULLISH (Raises: 2, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-09 | Goldman Sachs | $685 | $0 | 0% |
| 2025-12-08 | Keybanc | $750 | $0 | 0% |
| 2025-12-02 | Morgan Stanley | $670 | $656 | +2% |
| 2025-12-01 | HSBC | $670 | $550 | +22% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-09 | Goldman Sachs | init | Buy |
| 2025-12-08 | Keybanc | up | Overweight |
| 2025-12-02 | Morgan Stanley | main | Overweight |
| 2025-12-01 | HSBC | up | Buy |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 6 ($1.76M) |
| Sells | 14 ($41.68M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 38.8% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 8 / 2 |

**Top Holders:**
- Vanguard Group Inc: 9.0% (+0.2%)
- Blackrock Inc.: 7.9% (+8.4%)
- State Street Corpora: 4.4% (-0.6%)
- JPMORGAN CHASE & CO: 3.9% (+58.9%)
- Morgan Stanley: 3.4% (-1.2%)

### Key Risks

1. Momentum deterioration: MRS_10 falling (-2.4% 5d) with bearish MACD, trend may be turning.
2. Heavy insider selling: $42M sold (14 transactions in 90 days).
3. Market regime shift could impact momentum names disproportionately.

### Catalysts

- Share repurchase program provides demand floor and EPS support.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 1.95 elevated, pricing in significant growth expectations. Forward P/E 23.7x stretched relative to 8% growth. Balance sheet: $1.8B free cash flow. Analyst sentiment positive (2 raises, avg +12%). Insider selling cluster ($41.7M in 90 days), potential headwind. Institutional flow bullish (8 buying vs 2 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $215.6B |
| Beta | 0.90 |
| 52W Range | $385.46 - $610.97 |
| Short Interest | 1.4% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.95 |
| Forward P/E | 23.7 |
| Current P/E | 25.7 |
| YoY Growth | 8.4% |
| EPS Direction | STABLE |

### Technicals

MRS_10 deteriorating from 0.6% to -1.8% (-2.4% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 4.8pp (needs >3.0% for momentum thesis). Underperforming sector by 3.1pp, stock-specific weakness. Full SMA alignment bullish (above 20/50/200 SMAs). MACD histogram bearish (-0.84), momentum weakening. RSI neutral at 59.

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | -1.79% (CS: 30) | Neutral |
| RSI_14 | 59.1 | Neutral |
| MACD Histogram | -0.84 | Bearish |
| vs SMA20 | 1.011x | Above |
| vs SMA50 | 1.067x | Above |
| vs SMA200 | 1.219x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $585.15
- **Stop Loss:** $557.95 (4.6% risk)
- **Target:** $612.35 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 27
- **Position Value:** $15,799.05
- **Portfolio %:** 15.80%
- **Risk Dollars:** $750.00
- **Risk Per Trade:** 0.75%
- **Modifiers:** L1 100% | L2 75% | Combined 0.75x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | WEAKENING (Zone B) | 0.75x |

### Earnings

**Next:** 2026-01-29 (Est: $6.45)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $5.50 | $5.79 | +5.3% |
| 2025Q2 | $5.23 | $5.36 | +2.5% |
| 2025Q1 | $5.10 | $5.15 | +0.9% |
| 2024Q4 | $5.94 | $6.10 | +2.7% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_10*